Polygiene Group AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 sales declined 25% year-over-year, but gross margin improved to 69.5% due to disciplined pricing and cost control. Addmaster became the largest segment, while Polygiene sales dropped sharply. Innovation and actions to restore Americas growth are underway.
Fiscal Year 2025
-
Q4 sales fell 17.7% year-over-year, mainly due to FX and lower Polygiene sales, while Addmaster remained stable. Gross margin and EBITDA declined, impacted by FX and one-time CEO transition costs. Silver price volatility and regional demand shifts remain key challenges.
-
Q3 saw improved performance with Polygiene recovering and Addmaster lagging, but both segments show signs of recovery for Q4. Sales declined mainly due to FX, but new product launches and strong orders support a positive outlook.
-
Second quarter results were heavily impacted by tariffs and currency effects, leading to a 12% sales decline and negative EBITDA. Despite challenges, new product launches and a strategic U.S. partnership signal future growth, with recovery expected as external factors stabilize.
-
Revenue grew 18% year-over-year, with Polygiene segment up 42% and Admaster flat as expected. Gross margin remained strong at 67.4%, and the board proposed the first-ever dividend. New technologies and global expansion support a positive outlook for 2025.
Fiscal Year 2024
-
Sales grew 45% year-over-year, with strong Q4 margins and a proposed SEK 0.05 dividend. Both Polygiene and Addmaster segments saw robust growth, and new partnerships and product launches support a positive outlook for 2025.
-
Sales grew 42% year-over-year to SEK 40.8 million, with strong EBITDA and positive cash flow. Both Polygiene and Addmaster segments delivered robust growth, supported by new partnerships and innovation projects. Cash position remains strong and the company is debt-free.
-
Q2 saw 43% sales growth, improved profitability, and strong cash flow, driven by APAC—especially China—and successful business area separation. Gross margin declined due to mix and currency, but cost controls and innovation projects support a positive outlook.